The mitogen-activated protein (MAP) kinase SAPK/JNK phosphorylates tau protein at many of its proline-directed serine/ threonine residues in vitro and is a likely candidate kinase to phosphorylate the pathologically relevant S422 site on tau. Since phosphorylation of tau, particularly at S422, is a relatively early marker of AD and seems to precede tangle formation, it appears likely that an early form of activated SAPK/JNK might be detected by immunohistochemical means around the time that tau begins to aggregate into tangles. We report here that an antibody to phospho-SAPK/JNK (p-SAPK/JNK) reacts with several types of lesions including granular bodies in limbic areas; NFTs in limbic cortex and temporal neocortex; occasional neuritic plaques in temporal neocortex; and select axons in the hippocampus, entorhinal cortex, and inferior temporal cortex. In order to characterize the appearance of granular p-SAPK/JNK and determine if it appears early in disease, we employed an immunohistochemical study of postmortem limbic tissue from 20 cases ranging from Braak stages IYVI. By co-staining with anti-tau antibodies specific to different molecular events that occur during tangle evolution, we were able to identify the appearance of p-SAPK/JNK in early Braak stages with an increased elevation during the limbic stages of AD and during the early stages of the formation of individual hippocampal tangles.
INTRODUCTION
Alzheimer disease (AD) is characterized by the presence of beta amyloid peptide in the form of extracellular plaques (1) and hyperphosphorylated filamentous tau protein that forms neurofibrillary tangles (NFTs), neuropil threads, and the neuritic component of plaques (2) . The anatomical progression of tau pathology correlates with regional neurodegeneration (3) . NFTs and cell loss initially occur in the limbic system, particularly the entorhinal cortex and hippocampus, and progress to the neocortex (4) . Accompanying this process are clinical symptoms beginning with limbic deficits such as memory loss and eventually including disturbances in higher cortical functioning (5, 6) .
In concert with the anatomical progression, NFTs also undergo molecular changes during the course of AD. In this process, tau protein is abnormally hyperphosphorylated (7, 8) and truncated (9Y13) at multiple sites, accompanied by changes in its conformation (14Y16). Hyperphosphorylation can alter tau's affinity for microtubules (17, 18) and although some site-specific phosphorylation may protect against aggregation (17) , it is thought that the net effect of these modifications is to favor filament formation leading to intracellular accumulation of tau (19Y21). The availability of numerous antibodies that specifically recognize various tau epitopes when phosphorylated, truncated, or folded (reviewed in [22] ), have made it possible to track the temporal sequence of these changes in diseased brain by immunohistochemical means.
Proteins other than tau are found within many of the pathological tau lesions. Antibodies against active forms of several proline-directed serine/threonine kinases known to phosphorylate tau in vitro have been reported to react with neurofibrillary pathology. Glycogen synthase kinase-3 (GSK3) (23, 24) , cyclin-dependent kinase-5 (CDK5) (23) , and the mitogen-activated protein kinases (MAPKs): extra cellular signal-related kinase (ERK) (25Y28), p38 (25Y27, 29, 30) , and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK /JNK) (25Y30) all overlap to varying extents with neuritic pathology. GSK3 and the MAPKs, in particular, are found in 2 distinct types of inclusions: a fibrillar form which colocalizes with NFTs and a granular or punctate form that accumulates in morphologically healthy as well as tangle-bearing neurons (23Y31), suggesting that granular deposits may precede the formation of inclusions. Since phosphorylation of tau occurs early in NFT pathogenesis (8, 32, 33) , we hypothesize that the involvement of active kinases in tangle formation would be an early event as well, thus making a study of the granular form important.
We have focused the current study on the activated form of SAPK/JNK (p-SAPK/JNK) for the following reasons: The SAPK/JNK variants are activated by dual phosphorylation at Thr-183 and Tyr-185 and in turn phosphorylate tau at pathologically relevant sites, including Ser-422 (34, 35) , with high efficacy in vitro (34) . Moreover, p-SAPK/JNK levels are elevated in AD compared to control brain (36, 37) . Interestingly, SAPK/JNK is activated by beta-amyloid (AA) peptide (38Y 40) and is a critical component of the AAinduced toxicity pathway (38) , as is tau (41) . Finally, p-SAPK/ JNK regulates the activity of caspase-3 (42, 43) , the effector caspase thought to cleave tau at its C-terminus (10Y 12), leaving behind a fragment that aggregates more rapidly than full-length tau (10, 21) . In initial studies, we found consistent immunostaining with p-SAPK/JNK in limbic regions but not in the neocortex. Therefore, we limited our investigation to limbic areas. This study is designed to identify the chronological appearance of granular p-SAPK/JNK with respect to both overall disease progression and the maturation of individual NFTs in the CA1 region of the hippocampus and layers II and V of entorhinal cortex. A cohort of 20 cases ranging between Braak stages I and VI were double labeled with an antibody to p-SAPK/JNK and 3 anti-tau antibodies, Alz50, TauC3, and MN423, which recognize progressive molecular events in the maturation of the NFT. We found that p-SAPK/JNK appears in intraneuronal granules early during the onset of disease and is associated with early stages of hippocampal NFT formation.
MATERIALS AND METHODS

Primary Antibodies
The several monoclonal anti-tau antibodies were purified as described previously: Alz50 (44, 45) reacts with a discontinuous conformation-dependent epitope of tau (residues 7Y9 and 312Y342) in which the N-terminus of the molecule is folded onto the microtubule-binding region. TauC3 (10) recognizes C-terminal caspase-cleavage at Asp-421, and MN423 (46) recognizes C-terminal protease truncation at Glu-391. These 3 epitopes appear in a particular order such that adoption of the Alz50-conformation occurs first, followed by truncation at the TauC3 site, and further degradation at the MN423 site. The monoclonal tau antibody AT8, recognizing an early but prolonged phosphorylation-specific epitope (Ser202/Thr205) (47) was purchased from Endogen (#MN1020; Endogen, Rockford, IL). A polyclonal antibody recognizing dual phosphorylation (Thr-183/Tyr-185) of activated SAPK/JNK was obtained commercially (#9251; Cell Signaling Technology, Inc., Beverly, MA). We verified through Western blot analysis of total protein homogenates and paired helical filament-enriched homogenates from AD tissue that the p-SAPK/JNK antibody recognizes protein at the expected molecular weight of SAPK/JNK (data not shown).
Human Subjects
Postmortem fixed sections of hippocampus, entorhinal cortex, and temporal neocortex from 5 clinically diagnosed AD cases (Braak stages VYVI) and 10 clinically nondemented cases (Braak stages IYIV) were obtained from the Northwestern University Cognitive Neurology and Alzheimer's Disease Center. The corresponding tissue from 5 additional AD cases was obtained from the Rush Alzheimer's Disease Center. Demographic data for all cases is given in the Table 1 .
Double-Label Immunofluorescence and Confocal Microscopy
Free-floating, 40-Km-thick sections of hippocampus, entorhinal cortex, and the inferior, middle and superior gyri of the temporal cortex were immunostained according to a modified version of previously reported protocols (14, 48) and visualized by fluorescence microscopy. Specifically, following incubations in 0.4% TritonX-100 to permeabilize cell membranes, 3% H 2 0 2 /30% methanol to reduce blood vessel staining, and treatment with 3% horse serum/0.1% Triton to block non-specific binding, sections were double labeled overnight at 4-C with anti-p-SAPK/JNK (1:100 dilution of the supplied titer) and either Alz50 (0.84 Kg/mL), TauC3 (1 Kg/mL), or MN423 (0.1 Kg/mL). The antibodies were reacted with biotinylated-goat-anti-rabbit and TRITCconjugated goat-anti-mouse secondary antibodies (Jackson ImmunoResearch; West Grove, PA) overnight at 4-C. The p-SAPK/JNK signal was amplified by a two-hour reaction in ABC Elite (Vector Labs, Burlingame, CA) and further enhanced with FITC-tyramide, which was prepared by reacting 155.3 mg/mL of 5-(and-6)carboxyfluorescein-succinimidyl ester (Molecular Probes, Carlsbad, CA) dissolved in DMSO with 48.7 mg/mL tyramine (Sigma-Aldrich, St. Louis, MO) in DMSO at a 1:1 ratio (49, 50). The final solution was diluted 1:50,000 in 0.00015% H202/0.1M borate, pH 8.0, and applied to the tissue sections for 30 minutes. The sections were mounted onto ionized slides (Superfrost/Plus; Fisher Scientific, Pittsburgh, PA), treated with 2% Sudan black (Sigma-Aldrich) saturated in 70% ethanol for 3 minutes to minimize autofluorescence due to lipofuscin (51), differentiated in 70% ethanol, and coverslipped with Vectashield 
Quantitative Analysis of Fluorescently Labeled Cells
The relative distribution of p-SAPK/JNK labeling was compared to labeling of the 3 anti-tau antibodies, Alz-50, TauC3, and MN423. Systematic random samples, at 20Â magnification, were analyzed, resulting in counting fields measuring 0.6 mm by 0.44 mm and spaced 3 mm apart. The number of fields counted depended on the size of the region. Typically, in the CA1 region of the hippocampus and layer V of entorhinal cortex, there were 6 to 10 fields per region. In layer II of the entorhinal cortex, the 0.6 mm by 0.4 mm counting fields spanned the islands in such a way that at least a portion of each island was counted. At 20Â magnification, entorhinal layer II cells and layer V cells were never found within the same field. Sections were viewed on a Nikon E800 microscope by focusing using a Z motor, the top and bottom of the section were determined, and then an intermediate plane of focus was chosen at random. Images were captured in this plane by using a SPOT camera and SPOT version 4.1 software (Diagnostic Instruments, Sterling Heights, MI). Counting only the cells that appeared in focus, the number of cells and/or NFTs labeling with either or both of the antibodies was ascertained. Single-labeled and doublelabeled counts were averaged across fields in each region and for each case. Co-labeling of cells and NFTs was verified by confocal microscopy as previously described (14) .
Statistical Analyses
Analysis of variance (ANOVA) was used to assess the differences in staining patterns between different levels of pathological severity; pair-wise comparisons were assessed using Fisher's protected least significant difference (PLSD) post-hoc analysis. Bivariate regression analysis was used to compare the labeling of the p-SAPK/JNK antibody to the labeling of the different anti-tau antibodies. Differences in the regressions were calculated using t-tests (52) . ANOVA and regression statistics were performed using Statview 5.0.1 (SAS Institute Inc., Cary, NC); standard normal z-tests on the regression data were performed using SAS software (SAS Institute Inc.).
RESULTS p-SAPK/JNK Neuropathology in AD
The p-SAPK/JNK antibody reacted with a unique set of neuropathological structures in the tissue examined. Tangles with distinct fibrillar morphology (Fig. 1A) made up a subset of NFTs in the hippocampus and entorhinal cortex, particularly in Braak stages IVYVI. There was also profuse staining of punctate or granular p-SAPK/JNK throughout cells in the hippocampus and to a lesser extent in the entorhinal cortex (Fig. 1B) , which constituted the predominant form of p-SAPK/JNK staining in the 20 cases studied. In the inferior temporal gyrus of 4 of the 10 Braak stage VYVI cases studied, p-SAPK/JNK was found in neuritic plaques (Fig. 1C) . Finally, in all stages, p-SAPK/JNK-stained axons throughout the alveus of the hippocampus, layer I of the entorhinal cortex and occasionally in the plexiform layers of temporal neocortex (Fig. 1D) . In our hands, there was little p-SAPK/JNK neuropathology in non-temporal regions of AD brain tissue. To ensure that these observations were not contaminated by the autofluorescent lipofuscin commonly seen in the CNS cells of aged tissue, we treated the tissue with Sudan black (51) . Confocal microscopy of an unstained section of tissue from temporal cortex clearly reveals autofluorescence typical of lipofuscin (Fig. 1E) . Using the same confocal settings, Fig. 1F shows a large reduction in autofluorescence in non-immunostained tissue that has been treated with 2% Sudan black.
Quantification of Disease Progression and Pathological Cellular Severity
We sought to ascertain when granular p-SAPK/JNK first appears, both in terms of overall pathological disease progression and in terms of pathological severity within the cell. To quantify disease progression, we used a cohort of cases ranging from Braak stages IYVI (Table 1 ). The cases were divided into 3 groups corresponding to Braak stages IYII, IIIYIV, and VYVI. These groups are known as the Btransentorhinal stages,^the Blimbic stages,^and the Bisocortical stages,^respectively, and describe the furthest neuroanatomical progression of neuritic pathology at that stage (3, 4). There was no statistical difference in age, gender, or postmortem interval (PMI) among the 3 groups.
To assess pathological severity within cells, we employed 3 monoclonal antibodies to tau that recognize specific stages of tangle maturation. The Alz50 antibody stains pre-tangles and early NFTs, TauC3 recognizes tangles in an intermediate stage, and MN423 sees mature, late-stage tangles (12, 14) . Based on this evidence, cases with low Braak scores would be predicted to have fewer total tangles with a greater proportion of these tangles being Alz50-positive, while cases with high Braak scores would be predicted to have more total tangles with a greater proportion of these being MN423-positive. In addition, a greater proportion of MN423-tangles are expected in entorhinal cortex layers II (EC-L2) and V (EC-L5) compared to the CA1 region of the hippocampus (Hc-CA1) (Fig. 2) , based on data published by Braak and Braak (3, 4) .
Granular p-SAPK/JNK and Disease Progression
Cells containing granular p-SAPK/JNK were counted in the CA1 region of the hippocampus and layers II and V of entorhinal cortex. We found that in all 3 anatomical regions there is an augmentation in the number of cells containing p-SAPK/JNK granules in Braak stages III YIV when compared to Braak stages IYII (Fig. 3) . Specifically, analysis by ANOVA and the Fisher's PLSD test showed a significant 320% increase in the CA1 region of the hippocampus (F = 3.725, 2; p = 0.042) and a 240% increase in layer II of entorhinal cortex (F = 5.098, 2; p = 0.008). Although not statistically significant, there is a 200% increase in layer V of entorhinal cortex. In stages VYVI, the increase in p-SAPK/ JNK granule-containing cells when compared to Braak stages IYII persists and is significant in the CA1 region (F = 3.725, 2; p = 0.23) and layer II of entorhinal cortex (F = 5.098, 2; p = 0.045). It should also be noted that while levels of p-SAPK/JNK granules are similar in CA1, layer II and layer V in Braak stages IYII, in stages IIIYIV there is 150% increase of labeled cells in the CA1 region compared to layer II (p = NS) and a statistically significant 225% increase compared to layer V (p G 0.05). Similarly, in Braak stages VYVI, there is 200% increase in the number of granulecontaining CA1 cells compared to layer II (p G 0.05) and a 270% increase compared to layer V (p G 0.01). There is no correlation of granular p-SAPK/JNK levels with age, gender, PMI, or severity of amyloid deposition (data not shown), indicating that factors influencing early neuritic pathology, particularly in the CA1 of the hippocampus, may be influencing formation of granular p-SAPK/JNK as well.
Granular p-SAPK/JNK and Pathological Cellular Severity
To assess the temporal appearance of granular p-SAPK/ JNK with respect to NFT maturation within cells, sections of hippocampus and entorhinal cortex were double stained with p-SAPK/JNK and either Alz50, TauC3, or MN423. NFTs were double labeled with p-SAPK/JNK granules and Alz50, TauC3, or MN423 are shown in Figure 4 using confocal microscopy. While there is some colocalization with tau, most of the granules appear to reside in areas of the cell that do not contain fibrillar tau. The series of 3 double-labeled images of each pair of antibodies show a representative slice through the top, middle, and bottom z-axes of the cell or NFT, and shown below that are the projected threedimensional images of the full z-stack. Due to the fact that a large percentage of the p-SAPK/JNK granules were not found in NFT-bearing cells positive for Alz50, TauC3, or MN423, we used the phosphorylation-dependent tau antibody AT8, which recognizes morphologically normal neurons and pretangles as well as mature NFTs (33), to confirm the early nature of this phenomenon. We found that p-SAPK/JNK granules were found within the cytoplasm of several AT8-postive pyramidal neurons that appeared to be morphologically healthy and still contained intact processes (Fig. 4) .
Single-and double-labeled cells and NFTs were counted per 0.6 mm Â 0.44 mm field and averaged within the CA1 region and layers II and V of the entorhinal cortex. We found that a subset of cells containing p-SAPK/JNK granules co-label with Alz50, TauC3, and MN423 (Fig. 5A) . Approximately 20% of all p-SAPK/JNK granule-containing cells co-label with Alz50, approximately 5% co-label with TauC3, and slightly less than that co-label with MN423. Analysis by ANOVA and the Fisher PLSD test confirms that the degree of granule colocalization with Alz50 is significantly greater than with TauC3 or MN423 in the CA1 (F = 15.658, 2; p G 0.0001 for TauC3 and MN423 compared to Alz50), layer II (F = 10.642, 2; p = 0.0002 for TauC3 and MN423 compared to Alz50) and layer V (F = 7.609, 2; p = 0.0024 for TauC3 compared to Alz50 and p = 0.009 for MN423 compared to Alz50) and suggests that phosphorylation of tau by SAPK/JNK may occur relatively early during the formation of tangles within limbic areas.
In order to further examine the time at which p-SAPK/ JNK granules appear with respect to tau-epitope appearance, correlations between the number of co-labeled granular p-SAPK/JNK and tau cells were plotted against total Alz50+ (Fig. 5B), TauC3+ (Fig. 5C ), and MN423+ (Fig. 5D ) cells. A highly statistically significant correlation of R 2 = 0.71 was found between the number of Alz50 and granular p-SAPK/JNK co-labeled cells and all Alz50 cells (Fig. 5B ; p G 0.0001). In contrast, there was a correlation of R 2 = 0.56 between co-labeled p-SAPK/JNK/TauC3 cells and total TauC3 cells (Fig. 5C ; p G 0.0001), and a correlation of R 2 = 0.49 between co-labeled p-SAPK/JNK/MN423 cells and total MN423 cells (Fig. 5D ; p G 0.0001). Since a high percentage of granular p-SAPK/JNK is not co-resident in cells positive for Alz50, TauC3, or MN423, correlations were also plotted between total granular p-SAPK/JNK cells and each of the anti-tau antibodies (Fig. 5EYG) . Similarly, there is a higher correlation between total granular p-SAPK/JNK cells and the Alz50 antibody, with R 2 = 0.31, (Fig. 5E ; p G 0.0001), followed by a correlation of R 2 = 0.28 with the TauC3 antibody (Fig. 5F ; p G 0.0001). No correlation was found between total granular p-SAPK/JNK+ cells and total MN423+ cells ( Fig. 5G ; R 2 = 0.00, p = NS). Standard normal z-tests were performed on pairs of correlations, using the methods of Raghunathan et al (52) , in order to compare correlations with no common variables. Notably, there was a significant difference between the double labeling/Alz50 correlation (Fig. 5B ) and the double labeling/TauC3 correlation (Fig. 5C) , which further suggests that granules appear early during hippocampal NFT maturation (z = 1.96, p = 0.05). Taken together, this data provides strong evidence that p-SAPK/JNK granules form early in the onset of AD tau pathology and coincide more with the appearance of the Alz50-epitope than with later epitopes of tau characterized by the TauC3 and MN423 antibodies.
DISCUSSION SAPK/JNK and Apoptosis
SAPK/JNK is a particularly interesting candidate kinase for tau hyperphosphorylation due to its role in cellular stress (53, 54) and apoptosis (55, 56) . Although the SAPK/ JNK isoforms are involved in neuronal development and regulation of cytoskeletal stability, they largely play a neurodegenerative role by activating pro-apoptotic signaling molecules and inhibiting anti-apoptotic molecules (57) . However, DNA fragmentation, the end-stage marker of apoptosis, does not accompany neuritic p-SAPK/JNK pathology (58) . Moreover, there are conflicting reports as to whether end-stage apoptotic markers appear in neuronal tissue undergoing degeneration (32, 59 Y62). There are 2 possibilities for the dearth of evidence for apoptosis in neurons in vivo. The first is that apoptotic markers may be lost due to the loss of neurons. However, this would imply that cell death and clearance is a rapid process. The presence of large populations of intact neurons undergoing neurodegeneration seems to dispel this possibility. The other, more likely, scenario is that apoptotic signaling mechanisms are activated during the onset of neurodegeneration, but the process is never fully carried out.
Tangle Maturation
The anti-tau antibodies used in this study, Alz50, TauC3, and MN423, were selected for their ability to recognize epitopes of the tau molecule that arise during distinct stages of tangle evolution (12, 14) . One of the earliest events to occur in this maturation process is adoption by the tau molecule of the Alz50-epitope in which the N-terminus is folded onto the microtubule-binding region (44) . This is followed by carboxy-terminal truncation at Asp-421 by the apoptotic protease caspase-3 (as is recognized by the TauC3 antibody) (10 Y12) and ultimately further protease truncation to Glu-391 (MN423 antibody) (46) . Consequently, in AD tissue, Alz50 reacts with an early conformation of tau found in pre-tangles and intracellular NFTs (14, 63) , TauC3-tau appears in fibrillar intracellular tangles, and the MN423 antibody reacts with more mature extracellular tangles (64) . Some double labeling within tangles has been reported to occur between Alz50 and TauC3, but not between MN423 and either Alz50 or TauC3 (12, 14) , suggesting that these epitopes reflect distinct stages of tangle evolution.
Tau Phosphorylation and Truncation by Caspase
In addition to the conformational changes and truncations of tau that are observed by the above antibodies, phosphorylation of specific residues accompanies the maturation of tau within the tangle. In particular, phosphorylation of the Ser-422 residue on tau, one amino acid downstream of the caspase-3 cleavage site, is readily demonstrable in paired helical filament-tau but is only found in normal adult tau in trace amounts (65) . The Ser-422 site is a very good substrate for several of the SAPK/JNK isoforms and can also be phosphorylated, with slightly less affinity, by ERK. It is not easily phosphorylated by any of the non-MAP kinases that phosphorylate other sites on tau (34, 65) . Recent data in our lab demonstrates that Ser-422 phosphorylation regulates the ability of caspase-3 to cleave tau at Asp-421 (66) . Parenthetically, the C-terminus of tau beginning at Asp-421 acts as an inhibitory domain which, once irreversibly lost through caspase-3 cleavage, allows the remaining N-terminal fragment to polymerize more rapidly than full-length tau protein (10, 21) .
Protein Aggregation as a Form of Sequestration?
Two distinctive forms of p-SAPK/JNK are associated with neuritic pathology in Alzheimer disease. The fibrillar form has been widely reported to colocalize with fibrillar tau within NFTs (25 Y 27, 29, 30, 36, 37) . Granules, as shown in this report, correlate better with early markers of tau protein although they do not appear to greatly colocalize with fibrillar tau in these cells. One possibility is that the formation of granules is an attempt by the cell to sequester p-SAPK/ JNK and prevent the further activation of apoptotic mechanisms, similar to evidence suggesting that Lewy body formation in Parkinson disease may be a mechanism for substantia nigra neurons to sequester iron, thereby minimizing cellular damage due to oxidative stress (67) . The data presented in this paper shows that the majority of p-SAPK/ JNK granule-containing cells either do not contain fibrillar tau or contain fibrillar tau that has not yet been cleaved, suggesting an inhibition of caspase-activity and thus supporting this hypothesis. Perhaps p-SAPK/JNK that is not sequestered into granules becomes associated with tau during the process of NFT maturation, or maybe loss of granular structure allows free p-SAPK/JNK to associate with fibrillar tau, accounting for the prevalence of colocalization between fibrillar p-SAPK/JNK and NFT tau.
It is important to note 2 particular findings of this study. The first being that although granular p-SAPK/JNK co-labels with Alz50 to a greater extent than with TauC3 or MN423 (Fig. 5A) , and the number of cells containing granular p-SAPK/JNK correlates better with the number of Alz50+ tangles than with the number of TauC3+ or MN423+ tangles (Fig. 5B-G) , approximately 70% of granular p-SAPK/JNK does not co-label with the above 3 antibodies. However, when the AT8 antibody was used, we did see co-labeling with AT8+ pre-tangles. While colabeling of granular p-SAPK/JNK with AT8-pretangles supports our quantitative data, suggesting that granular p-SAPK/JNK appears in limbic areas during the early formation of tangles, we do not presume that the majority of p-SAPK/JNK granules reside in cells undergoing the early stages of tangle formation. Rather, it is much more likely that similar processes (i.e. apoptosis and oxidative stress), which contribute to the formation of tangles in a population of cells, also contribute to the formation of granular bodies containing p-SAPK/JNK.
The second finding of note is that although we conclude that p-SAPK/JNK is an early event in Alzheimer's disease pathogenesis, we see a large increase in the number of p-SAPK/JNK granule-containing cells during Braak stages IIIYIV. This occurrence is not contradictory however. In Braak stages IYII, tangles begin to form primarily in the trans-entorhinal areas. Early tangle formation is not seen in the hippocampus or entorhinal cortex until stages IIIYIV (3, 4) . Furthermore, the Alz50 and TauC3 epitopes do not appear in great numbers of NFTs in the CA1 region until Braak stages IIIYIV (Fig. 2) . Since granular p-SAPK/JNK is found primarily within limbic cortex and is rare in the neocortex, we believe that augmentation of these granules during Braak stages IIIYIV accompanies the onset of tau pathology in the hippocampus and entorhinal cortex. There are several possibilities as to why this may occur. Conceivably, cortical cells may have not yet experienced the degree of neurodegeneration that limbic cells have. Or perhaps upregulation of p-SAPK/JNK within the hippocampus causes aggregation into granules by the rules of mass action. Another possibility is that p-SAPK/JNK is activated and phosphorylates tau in most regions with abundant tau pathology but a factor unique to hippocampal pyramidal neurons causes the sequestration of p-SAPK/JNK into granules. Thus, the role of p-SAPK/JNK in the hippocampus during disease merits further investigation.
